Iterative	B:C1854293
Development	O
and	O
Evaluation	O
of	O
a	O
Pharmacogenomic	O
-	O
Guided	O
Clinical	O
Decision	I:C0525070
Support	I:C0525070
System	I:C0525070
for	O
Warfarin	O
Dosing	O
.	O

Iterative	O
Development	O
and	O
Evaluation	B:C0220825
of	O
a	O
Pharmacogenomic	O
-	O
Guided	O
Clinical	O
Decision	I:C0525070
Support	I:C0525070
System	I:C0525070
for	O
Warfarin	O
Dosing	O
.	O

Iterative	O
Development	O
and	O
Evaluation	O
of	O
a	O
Pharmacogenomic	B:C1138555
-	O
Guided	O
Clinical	O
Decision	I:C0525070
Support	I:C0525070
System	I:C0525070
for	O
Warfarin	O
Dosing	O
.	O

Iterative	O
Development	O
and	O
Evaluation	O
of	O
a	O
Pharmacogenomic	O
-	O
Guided	O
Clinical	B:C0525070
Decision	I:C0525070
Support	I:C0525070
System	I:C0525070
for	O
Warfarin	O
Dosing	O
.	O

Pharmacogenomic	B:C1138555
-	O
guided	O
dosing	O
has	O
the	O
potential	O
to	O
improve	O
patient	O
outcomes	O
but	O
its	O
implementation	O
has	O
been	O
met	O
with	O
clinical	O
challenges	O
.	O

Pharmacogenomic	O
-	O
guided	O
dosing	O
has	O
the	O
potential	O
to	O
improve	O
patient	O
outcomes	O
but	O
its	O
implementation	O
has	O
been	O
met	O
with	O
clinical	O
challenges	B:C0805586
.	O

Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	B:C0220825
a	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
(	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
)	O
for	O
pharmacogenomic	O
-	O
guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	O
and	O
pharmacists	O
.	O

Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	O
a	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
(	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
)	O
for	O
pharmacogenomic	O
-	O
guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	O
and	O
pharmacists	O
.	O

Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	O
a	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
(	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
)	O
for	O
pharmacogenomic	O
-	O
guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	O
and	O
pharmacists	O
.	O

Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	O
a	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
(	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
)	O
for	O
pharmacogenomic	B:C1138555
-	O
guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	O
and	O
pharmacists	O
.	O

Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	O
a	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
(	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
)	O
for	O
pharmacogenomic	O
-	O
guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	B:C0031831
and	O
pharmacists	O
.	O

Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	O
a	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
(	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
)	O
for	O
pharmacogenomic	O
-	O
guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	O
and	O
pharmacists	B:C0031323
.	O

Twelve	O
physicians	B:C0031831
and	O
pharmacists	O
completed	O
6	O
prescribing	O
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	O
(	O
development	O
and	O
validation	O
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	O
-	O
driven	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
prototype	O
.	O

Twelve	O
physicians	O
and	O
pharmacists	B:C0031323
completed	O
6	O
prescribing	O
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	O
(	O
development	O
and	O
validation	O
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	O
-	O
driven	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
prototype	O
.	O

Twelve	O
physicians	O
and	O
pharmacists	O
completed	O
6	O
prescribing	O
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	B:C1854293
(	O
development	O
and	O
validation	O
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	O
-	O
driven	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
prototype	O
.	O

Twelve	O
physicians	O
and	O
pharmacists	O
completed	O
6	O
prescribing	O
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	O
(	O
development	O
and	O
validation	B:C1519941
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	O
-	O
driven	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
prototype	O
.	O

Twelve	O
physicians	O
and	O
pharmacists	O
completed	O
6	O
prescribing	O
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	O
(	O
development	O
and	O
validation	O
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	B:C1138555
-	O
driven	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
prototype	O
.	O

Twelve	O
physicians	O
and	O
pharmacists	O
completed	O
6	O
prescribing	O
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	O
(	O
development	O
and	O
validation	O
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	O
-	O
driven	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
prototype	O
.	O

For	O
each	O
scenario	O
,	O
usability	O
was	O
measured	O
via	O
efficiency	O
,	O
recorded	B:C0034869
as	O
time	O
to	O
task	O
completion	O
,	O
and	O
participants	O
'	O
perceived	O
satisfaction	O
which	O
were	O
compared	O
using	O
Kruskal	O
-	I:C0282574
Wallis	I:C0282574
and	I:C0282574
Mann	I:C0282574
Whitney	I:C0282574
U	I:C0282574
tests	I:C0282574
,	O
respectively	O
.	O

For	O
each	O
scenario	O
,	O
usability	O
was	O
measured	O
via	O
efficiency	O
,	O
recorded	O
as	O
time	O
to	O
task	O
completion	O
,	O
and	O
participants	B:C0679646
'	O
perceived	O
satisfaction	O
which	O
were	O
compared	O
using	O
Kruskal	O
-	I:C0282574
Wallis	I:C0282574
and	I:C0282574
Mann	I:C0282574
Whitney	I:C0282574
U	I:C0282574
tests	I:C0282574
,	O
respectively	O
.	O

For	O
each	O
scenario	O
,	O
usability	O
was	O
measured	O
via	O
efficiency	O
,	O
recorded	O
as	O
time	O
to	O
task	O
completion	O
,	O
and	O
participants	O
'	O
perceived	B:C0030971
satisfaction	O
which	O
were	O
compared	O
using	O
Kruskal	O
-	I:C0282574
Wallis	I:C0282574
and	I:C0282574
Mann	I:C0282574
Whitney	I:C0282574
U	I:C0282574
tests	I:C0282574
,	O
respectively	O
.	O

For	O
each	O
scenario	O
,	O
usability	O
was	O
measured	O
via	O
efficiency	O
,	O
recorded	O
as	O
time	O
to	O
task	O
completion	O
,	O
and	O
participants	O
'	O
perceived	O
satisfaction	B:C0242428
which	O
were	O
compared	O
using	O
Kruskal	O
-	I:C0282574
Wallis	I:C0282574
and	I:C0282574
Mann	I:C0282574
Whitney	I:C0282574
U	I:C0282574
tests	I:C0282574
,	O
respectively	O
.	O

For	O
each	O
scenario	O
,	O
usability	O
was	O
measured	O
via	O
efficiency	O
,	O
recorded	O
as	O
time	O
to	O
task	O
completion	O
,	O
and	O
participants	O
'	O
perceived	O
satisfaction	O
which	O
were	O
compared	O
using	O
Kruskal	B:C0282574
-	I:C0282574
Wallis	I:C0282574
and	I:C0282574
Mann	I:C0282574
Whitney	I:C0282574
U	I:C0282574
tests	I:C0282574
,	O
respectively	O
.	O

Debrief	O
interviews	O
were	O
conducted	O
and	O
qualitatively	B:C0022885
analyzed	I:C0022885
.	O

Usability	O
findings	O
from	O
the	O
first	O
(	O
i.e.	O
development	O
)	O
iteration	B:C1854293
were	O
incorporated	O
into	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
design	O
for	O
the	O
second	O
(	O
i.e.	O
validation	O
)	O
iteration	O
.	O

Usability	O
findings	O
from	O
the	O
first	O
(	O
i.e.	O
development	O
)	O
iteration	O
were	O
incorporated	O
into	O
the	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
design	O
for	O
the	O
second	O
(	O
i.e.	O
validation	O
)	O
iteration	O
.	O

Usability	O
findings	O
from	O
the	O
first	O
(	O
i.e.	O
development	O
)	O
iteration	O
were	O
incorporated	O
into	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
design	O
for	O
the	O
second	O
(	O
i.e.	O
validation	B:C1519941
)	O
iteration	O
.	O

Usability	O
findings	O
from	O
the	O
first	O
(	O
i.e.	O
development	O
)	O
iteration	O
were	O
incorporated	O
into	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
design	O
for	O
the	O
second	O
(	O
i.e.	O
validation	O
)	O
iteration	B:C1854293
.	O

During	O
the	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
validation	O
iteration	O
,	O
participants	O
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
of	O
183	O
(	O
124-247	O
)	O
seconds	O
versus	O
101	O
(	O
73.5	O
-	O
197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	O
(	O
p=0.01	O
)	O
.	O

During	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
validation	B:C1519941
iteration	O
,	O
participants	O
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
of	O
183	O
(	O
124-247	O
)	O
seconds	O
versus	O
101	O
(	O
73.5	O
-	O
197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	O
(	O
p=0.01	O
)	O
.	O

During	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
validation	O
iteration	B:C1854293
,	O
participants	O
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
of	O
183	O
(	O
124-247	O
)	O
seconds	O
versus	O
101	O
(	O
73.5	O
-	O
197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	O
(	O
p=0.01	O
)	O
.	O

During	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
validation	O
iteration	O
,	O
participants	B:C0679646
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
of	O
183	O
(	O
124-247	O
)	O
seconds	O
versus	O
101	O
(	O
73.5	O
-	O
197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	O
(	O
p=0.01	O
)	O
.	O

During	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
validation	O
iteration	O
,	O
participants	O
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	B:C0549183
(	O
IQR	O
)	O
of	O
183	O
(	O
124-247	O
)	O
seconds	O
versus	O
101	O
(	O
73.5	O
-	O
197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	O
(	O
p=0.01	O
)	O
.	O

During	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
validation	O
iteration	O
,	O
participants	O
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
of	O
183	O
(	O
124-247	O
)	O
seconds	O
versus	O
101	O
(	O
73.5	O
-	O
197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	B:C1854293
(	O
p=0.01	O
)	O
.	O

This	O
increase	O
in	O
time	O
on	O
task	O
was	O
due	O
to	O
the	O
increase	O
in	O
time	O
spent	O
in	O
the	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
corresponding	O
to	O
several	O
design	O
changes	O
.	O

Efficiency	O
differences	O
that	O
were	O
observed	O
between	O
pharmacists	B:C0031323
and	O
physicians	O
in	O
the	O
development	O
iteration	O
were	O
eliminated	O
in	O
the	O
validation	O
iteration	O
.	O

Efficiency	O
differences	O
that	O
were	O
observed	O
between	O
pharmacists	O
and	O
physicians	B:C0031831
in	O
the	O
development	O
iteration	O
were	O
eliminated	O
in	O
the	O
validation	O
iteration	O
.	O

Efficiency	O
differences	O
that	O
were	O
observed	O
between	O
pharmacists	O
and	O
physicians	O
in	O
the	O
development	O
iteration	B:C1854293
were	O
eliminated	O
in	O
the	O
validation	O
iteration	O
.	O

Efficiency	O
differences	O
that	O
were	O
observed	O
between	O
pharmacists	O
and	O
physicians	O
in	O
the	O
development	O
iteration	O
were	O
eliminated	O
in	O
the	O
validation	B:C1519941
iteration	O
.	O

Efficiency	O
differences	O
that	O
were	O
observed	O
between	O
pharmacists	O
and	O
physicians	O
in	O
the	O
development	O
iteration	O
were	O
eliminated	O
in	O
the	O
validation	O
iteration	B:C1854293
.	O

The	O
increased	O
use	O
of	O
the	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
recommended	O
doses	O
in	O
the	O
validation	O
iteration	O
(	O
4	O
%	O
in	O
the	O
first	O
iteration	O
vs.	O
37.5	O
%	O
in	O
the	O
second	O
iteration	O
,	O
p<0.001	O
)	O
.	O

The	O
increased	O
use	O
of	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
recommended	O
doses	O
in	O
the	O
validation	O
iteration	O
(	O
4	O
%	O
in	O
the	O
first	O
iteration	O
vs.	O
37.5	O
%	O
in	O
the	O
second	O
iteration	O
,	O
p<0.001	O
)	O
.	O

The	O
increased	O
use	O
of	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
recommended	O
doses	O
in	O
the	O
validation	B:C1519941
iteration	O
(	O
4	O
%	O
in	O
the	O
first	O
iteration	O
vs.	O
37.5	O
%	O
in	O
the	O
second	O
iteration	O
,	O
p<0.001	O
)	O
.	O

The	O
increased	O
use	O
of	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
recommended	O
doses	O
in	O
the	O
validation	O
iteration	B:C1854293
(	O
4	O
%	O
in	O
the	O
first	O
iteration	O
vs.	O
37.5	O
%	O
in	O
the	O
second	O
iteration	O
,	O
p<0.001	O
)	O
.	O

The	O
increased	O
use	O
of	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
recommended	O
doses	O
in	O
the	O
validation	O
iteration	O
(	O
4	O
%	O
in	O
the	O
first	O
iteration	B:C1854293
vs.	O
37.5	O
%	O
in	O
the	O
second	O
iteration	O
,	O
p<0.001	O
)	O
.	O

The	O
increased	O
use	O
of	O
the	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
recommended	O
doses	O
in	O
the	O
validation	O
iteration	O
(	O
4	O
%	O
in	O
the	O
first	O
iteration	O
vs.	O
37.5	O
%	O
in	O
the	O
second	O
iteration	B:C1854293
,	O
p<0.001	O
)	O
.	O

Overall	O
satisfaction	B:C0242428
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	O
but	O
the	O
qualitative	O
analysis	I:C0022885
revealed	O
greater	O
trust	O
in	O
the	O
second	O
prototype	O
.	O

Overall	O
satisfaction	O
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	B:C1854293
but	O
the	O
qualitative	O
analysis	I:C0022885
revealed	O
greater	O
trust	O
in	O
the	O
second	O
prototype	O
.	O

Overall	O
satisfaction	O
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	O
but	O
the	O
qualitative	B:C0022885
analysis	I:C0022885
revealed	O
greater	O
trust	O
in	O
the	O
second	O
prototype	O
.	O

A	O
pharmacogenomic	B:C1138555
-	O
guided	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
has	O
been	O
developed	O
using	O
warfarin	O
as	O
the	O
test	O
drug	O
.	O

A	O
pharmacogenomic	O
-	O
guided	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
has	O
been	O
developed	O
using	O
warfarin	O
as	O
the	O
test	O
drug	O
.	O

A	O
pharmacogenomic	O
-	O
guided	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
has	O
been	O
developed	O
using	O
warfarin	B:C0043031
as	O
the	O
test	O
drug	O
.	O

A	O
pharmacogenomic	O
-	O
guided	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
has	O
been	O
developed	O
using	O
warfarin	O
as	O
the	O
test	O
drug	B:C1254351
.	O

The	O
final	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
prototype	O
was	O
trusted	O
by	O
prescribers	O
and	O
significantly	O
increased	O
the	O
time	O
using	O
the	O
tool	O
and	O
acceptance	O
of	O
the	O
recommended	O
doses	O
.	O

This	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	B:C1138555
into	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
design	O
for	O
clinical	O
testing	I:C1516634
.	O

This	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	O
into	O
clinical	B:C0525070
decision	I:C0525070
support	I:C0525070
system	I:C0525070
design	O
for	O
clinical	O
testing	I:C1516634
.	O

This	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	O
into	O
clinical	O
decision	I:C0525070
support	I:C0525070
system	I:C0525070
design	O
for	O
clinical	B:C1516634
testing	I:C1516634
.	O

